

**2024 (August 2023- August 2024) Inpatient Data - All sources other than urine
(MHMH, APD, NLH)**

For use by providers within the DH system only. Please do not share with pharmaceutical representatives.



Organisms

Per CLSI guidelines, there should be 30 or more isolates to be considered statistically adequate for selecting antibiotics for treatment.

Number of Isolates	Penicillin	Ampicillin	Ox/Nafcillin	Ampicillin/Sulbactam	Piperacillin/Tazo	Cefazolin (first)	Cefuroxime (second)	CeftAZidime (third)	CefTRIaxone (third)	Cefepime (fourth)	Meropenem	Daptomycin	Linezolid	Gentamicin	Tobramycin	Vancomycin	Clindamycin	Erythromycin	Metronidazole	Tetracycline	Trimethoprim-sulfa	Ciprofloxacin	Levofloxacin
--------------------	------------	------------	--------------	----------------------	-------------------	-------------------	---------------------	---------------------	---------------------	-------------------	-----------	------------	-----------	------------	------------	------------	-------------	--------------	---------------	--------------	--------------------	---------------	--------------

GRAM POSITIVES

Staphylococcus aureus - ALL ¹	861		61			61						100	100	100 ²		100	75	51		91	88	72	73
- <i>Staphylococcus aureus</i> - MSSA	526		100			100						99	100	100 ²		100	82	72		96	98	92	93
- <i>Staphylococcus aureus</i> - MRSA	335		0			0						100 ³	100	100 ²		100	64	17		84	72	39	41
<i>Staphylococcus lugdunensis</i>	41		93			93							100	100 ²		100	83	85		93	100	100	100
<i>Staphylococcus coagulase negative sp.</i>	153		47			47						100	100	92 ²		100	58	46		82	67	75	76
<i>Streptococcus pneumoniae</i>	34	77							97		91					100		71		79	85		100
- <i>Streptococcus pneumoniae</i> (meningitis)	34	76							97														
<i>Enterococcus faecium</i>	47	19	19			0	0	0	0	0		93 ^{3,4}	100	96 ^{2,5}		28	0	4		17			
<i>Enterococcus faecalis</i>	101	100	100			0	0	0	0	0		100 ³	100	85 ^{2,5}		97	0	21		25			
<i>Strep. anginosus</i> grp (<i>S. milleri</i>)	72	100 ⁶							100 ⁶														100 ⁶
<i>Cutibacterium acnes</i>	36	100									100						92						

GRAM NEGATIVES

<i>Haemophilus influenzae</i>	54		74 ⁷																				
<i>Escherichia coli</i>	280		62 ⁸		69	94	86 ⁸	88 ⁸	91 ⁹	87	90	100		92	92 ⁹					84 ⁹	85	84 ⁸	81
<i>Enterobacter cloacae</i> complex	71		0		81	0		77 ⁹	70	88	100			96	92 ⁹					100 ⁹	87	91 ⁸	90
<i>Klebsiella oxytoca</i>	39		0		77	90			90	100	100			100							97		97
<i>Klebsiella pneumoniae</i>	109		0		79	94	90 ⁸	87 ⁸	86 ⁹	87	85	99		97	90 ⁹					81 ⁹	89	91 ⁸	94
<i>Proteus mirabilis</i>	44				89	98		98 ⁹	96	100				91	95 ⁹					0 ⁹	93		96
<i>Pseudomonas aeruginosa</i>	163		0		85			82	80	95					98							86	84
<i>Serratia marcescens</i>	57		0		0	0	85 ⁹	86	96	100				98	94 ⁹					31 ⁹	98		100
<i>Stenotrophomonas maltophilia</i>	37																				92 ¹⁰		78 ¹⁰
<i>Bacteroides fragilis</i> group	31				84 ¹¹														97 ¹¹				

¹ 39% of all *Staphylococcus aureus* isolates from DH inpatient (APD/NLH/MHMH) non-urine sources are MRSA.
² Gentamicin should not be used for monotherapy.
³ Daptomycin: MRSA n=108, *E. faecalis* n=53, *E. faecium* n=58 (combined years 2023+2024).
⁴ Susceptible dose-dependent based on daptomycin doses of 10-12 mg/kg/day
⁵ Synergy is predicted for therapy with penicillin, ampicillin, or vancomycin combined with gentamicin.
⁶ Penicillin n=72, ceftriaxone & levofloxacin n = 54.
⁷ Negative β-lactamase predicts susceptibility to ampicillin.
⁸ Ampicillin, Cefazolin, Cefuroxime, Ciprofloxacin: n is approximately 50% lower than the reported number of isolates.
⁹ Ceftazidime, aztreonam, tobramycin, tetracycline: n is approximately 20% lower than the reported number of isolates.
¹⁰ Trimethoprim-sulfa and Levofloxacin should not be used alone for antimicrobial therapy.
¹¹ *B. fragilis* group: 2023 & 2024 data combined.

For use by providers within the DH system only. Please do not share with pharmaceutical representatives.